USP7 (IC50 = 1.4 μM)

USP7 or HAUSP (herpesvirus-associated USP) is a deubiquitylating enzyme that cleaves ubiquitin from its substrates. It is also known as a ubiquitin-specific protease. USP7 is a eubiquitinase (DUB) that modifies the stability of Mdm2, p53, PTEN, and FOXO4 in order to regulate cell proliferation.

---

At 15 μM, GNE-6776 significantly inhibits USP7. A highly selective USP7 inhibitor against endogenous cellular deubiquitinases as well as recombinant ones is GNE-6776[1]. GNE-6776 induced tumour cell death and enhance cytotoxicity with chemotherapeutic agents and targeted compounds, including PIM kinase inhibitors. Structural studies reveal that GNE-6640 and GNE-6776 non-covalently target USP7 12 Å distant from the catalytic cysteine. The compounds attenuate ubiquitin binding and thus inhibit USP7 deubiquitinase activity. GNE-6640 and GNE-6776 interact with acidic residues that mediate hydrogen-bond interactions with the ubiquitin Lys48 side chain, suggesting that USP7 preferentially interacts with and cleaves ubiquitin moieties that have free Lys48 side chains.[1]

GNE-6776 inhibits the growth of EOL-1 xenografts in mice when given orally once or twice a day for ten days at a dose of 100 or 200 mg/kg. [1]. Given the favourable features of these inhibitors, we investigated their efficacy in animal models. Pharmacodynamic and pharmacokinetic studies indicated that GNE-6776 is orally bioavailable and promotes on-target pathway modulation in human xenografts (Extended Data Fig. 4e–i). Although efficacious exposure was only transiently achieved, GNE-6776 caused modest, although significant, EOL-1 xenograft growth delay (Extended Data Fig. 4j). Developing USP7 inhibitors that have improved drug-like properties will be necessary to comprehensively evaluate USP7 inhibition in vivo.[1]

USP7 enzymatic analysis[1]
Michaelis–Menten kinetic measurements with full-length USP7 were performed using 1 nM USP7 with a series of ubiquitin–AMC substrate titrations. The initial rate of substrate hydrolysis was determined using the Magellan software on a Tecan Safire2 plate reader, and kinetic parameters modelled using nonlinear regression analysis with GraphPad Prism software. Standard error was calculated from three technical replicates. For studies using the USP7 D305/E308 mutant, samples were reacted in a buffer consisting of 50 mM HEPES (pH 7.5), 100 mM NaCl, 2.5 mM dithiothreitol, and 0.1% (w/v) bovine gamma globulin. The starting substrate concentration of ubiquitin-Rho110 used for the Michaelis–Menten analysis was 100 μM serial diluted to 781 nM. Reactions were performed for 1 h at room temperature with a final enzyme concentration of 100 nM (three independent experiments, see symbols in plots), in black 100-μl volume 96-well half area plates. The enzymatic activity was calculated by fitting the data using the initial velocity with the linear V0 values measured by analysing the fluorescence signal of cleaved Rho-110 using excitation at 485 nm and emission at 535 nm.

---

Deubiquitinase selectivity analysis[1]
Recombinant deubiquitinase di-ubiquitin mass spectrometry cleavage assay. The MALDI–TOF DUB assay was performed using the indicated concentrations of recombinant deubiquitinases, di-ubiquitin substrates, and USP7 inhibitor compounds as described previously. The inhibition efficiency for GNE-6640 and GNE-6776 against the UCHl family members was monitored on Ub-Ube2W (Ub-E2), an alternative substrate to di-ubiquitin.

---

Cell Assay Tumour cell-line panel viability. [1]
GNE-6640 and GNE-6641 were profiled for 3 days across 441 cell lines, and GNE-6776, GNE-6640, and GNE-6641 were profiled for 5 days across a subset of 185 cell lines as previously described26. In brief, compounds were screened in nine-point dose–response using a threefold dilution. Cells were seeded into 384-well plates 24 h before compound addition. Cells were then incubated with compound for 72 h or 120 h before assaying viability. Assays were performed in biological triplicate. Cells were incubated (37 °C, 5% CO2) in RPMI-1640, 2.5% FBS (72 h assay) or 5% FBS (120 h assay), and 2 mM glutamine throughout the assay. The reported IC50 and mean viability metrics were as follows: IC50 was the dose at which the estimated inhibition was 50% relative to untreated wells (that is, absolute IC50).

Tumour cell-line panel viability. [1]
GNE-6640 and GNE-6641 were profiled for 3 days across 441 cell lines, and GNE-6776, GNE-6640, and GNE-6641 were profiled for 5 days across a subset of 185 cell lines as previously described26. In brief, compounds were screened in nine-point dose–response using a threefold dilution. Cells were seeded into 384-well plates 24 h before compound addition. Cells were then incubated with compound for 72 h or 120 h before assaying viability. Assays were performed in biological triplicate. Cells were incubated (37 °C, 5% CO2) in RPMI-1640, 2.5% FBS (72 h assay) or 5% FBS (120 h assay), and 2 mM glutamine throughout the assay. The reported IC50 and mean viability metrics were as follows: IC50 was the dose at which the estimated inhibition was 50% relative to untreated wells (that is, absolute IC50).

---

Primary combination screen. [1]
A compound library comprising 589 compounds arrayed in nine-point dose–response was screened in the absence or presence of fixed doses of GNE-6776 (0 nm, 125 nM, 250 nM, 500 nM, 1,000 nM, and 2,000 nM) or GNE-6640 (400 nM). In brief, 5,000 EOL-1 cells were seeded into 384-well plates, and compound was added 24 h later. Cell viability was determined 120 h after compound addition (CellTiter-Glo). Curves were fitted, and both IC50 and mean viability metrics were calculated. The IC50 was the dose at which inhibition was 50% relative to untreated wells. The mean viability was the average of the fitted viabilities at each tested dose. Mean viability was equivalent to the area under the log-dose/viability curve divided by the total number of tested doses. Mean viability values were used for the analysis described in Extended Data Fig. 6g. All data were fitted using Genedata Screener software.

---

Primary combination screen analysis. [1]
Normalized mean viabilities were determined in the EOL-1 cell line for 574 compounds that have known protein or mechanistic targets, in the presence of DMSO or increasing concentrations of GNE-6776 (100 nM, 250 nM, 500 nM, 1,000 nM or 2,000 nM) or 400 nM of GNE-6640. For each compound, we assessed the difference in mean viability between USP7 inhibitor treatment and the DMSO treatment. For targets targeted by three or more compounds, we calculated the enrichment of high mean viability difference for each concentration of USP7 inhibitor by using a Wilcoxon rank-sum test. For visualization purposes, we combined the results of all concentrations by taking the mean of the −log10(transformed P values) for each target.

Immunodeficient C.B-17 SCID mice with an EOL1 AML xenograft, aged 12–16 weeks[1]
100 or 200 mg/kg

---

DMPK analysis. [1]
In vitro DMPK studies were performed using standard protocols. GNE-6776 was formulated as a suspension in 0.5% methylcellulose/0.2% Tween-80 and was administered at 200 mg kg−1 (body weight) by oral gavage to female C.B-17 SCID mice, aged 12–16 weeks (n = 3 per time point). No randomization was used for DMPK studies. At 0.5, 1, 2, 4, 8 and 24 h post-dose, blood samples were collected by terminal cardiac puncture into anticoagulant tubes (EDTA). Clarified plasma was then transferred to a fresh tube and snap frozen. GNE-6776 plasma concentrations were determined by LC–MS/MS.

---

In vivo pharmacodynamic response. [1]
For EOL-1 AML xenograft studies, immunodeficient C.B-17 SCID mice, aged 12–16 weeks, were inoculated subcutaneously on the right flank with five million cells in a 50:50 suspension of HBSS:Matrigel (100 μl). When tumour volumes reached between approximately 285 and 500 mm3, mice were distributed into volume-matched cohorts (n = 4). For MCF7 breast-cancer xenograft studies, immunodeficient nu/nu mice, aged 6–8 weeks, were implanted with 0.36 mg oestrogen pellets via trochar 1–3 days before tumour cell inoculation. Ten million MCF7-Ser cells, an in vivo-optimized MCF7 variant, were injected orthotopically into the 2/3 mammary fat pad of each mouse in a 50:50 suspension of HBSS:Matrigel in a total volume of 100 μl. When tumour volumes reached between approximately 285 and 450 mm3, mice were distributed into volume-matched cohorts (n = 4). GNE-6776 was formulated as a suspension in 0.5% methylcellulose/0.2% Tween-80 and administered at 200 mg kg−1 (body weight) by oral gavage at 0 and 4 h. 0.5% Methylcellulose/0.2% Tween-80 control or GNE-6776-treated samples were collected at 8 h after the first dose and excised tumours were flash-frozen on dry ice. Tumours were lysed in RIPA buffer containing protease inhibitors and 300 mM NaCl using a Qiagen TissueLyser. Samples were incubated on ice for 15 min and then centrifuged at 20,000g at 4 °C for 10 min. Protein levels in clarified lysates were quantified using a Pierce BCA assay kit and concentrations were normalized with sample buffer. Samples were run on gels, and proteins were transferred to membranes and western blotted as described above.

---

In vivo efficacy study. [1]
For EOL1 AML xenograft studies, immunodeficient C.B-17 SCID mice (Charles River Laboratories), aged 12–16 weeks, were inoculated subcutaneously on the right flank with five million cells in a 50:50 suspension of HBSS:Matrigel (100 μl). When tumours became established (150–300 mm3), mice were distributed into tumour-volume-matched cohorts (n = 7, mean tumour volume ~250 mm3). GNE-6776 was formulated as a suspension in 0.5% methylcellulose/0.2% Tween-80 and was administered at 100 or 200 mg kg−1 (body weight) by oral gavage on a once or twice daily schedule. Tumour volume measurements, body weight and body condition data were collected two or three times per week. The maximum tumour volume limit of 2,000 mm3 was not reached in any animal.

[1]. Usp7 inhibitor compounds and methods of use. US20160272588A1.

The ubiquitin system regulates important cellular processes in eukaryotes. Ubiquitins are linked to substrate proteins in monomeric or chain form, and the topological structure modified by ubiquitin regulates the interaction between substrates and specific proteins. Therefore, ubiquitination determines the fate of a variety of substrates, including proteasome degradation. Deubiquitinating enzymes cleave ubiquitin from substrates and are associated with a variety of diseases; for example, ubiquitin-specific protease-7 (USP7) regulates the stability of p53 tumor suppressor protein and other proteins essential for tumor cell survival. However, developing selective deubiquitinating enzyme inhibitors has been extremely challenging, and the co-crystal structures of small molecule inhibitors and deubiquitinating enzymes have not yet been resolved. In this paper, we describe the development of the selective USP7 inhibitors GNE-6640 and GNE-6776 using NMR-based screening and structure-based drug design. These compounds induce tumor cell death and enhance the cytotoxicity of chemotherapeutic drugs and targeted compounds, including PIM kinase inhibitors. Structural studies revealed that GNE-6640 and GNE-6776 non-covalently target USP7, with their action sites located 12 Å from the catalytic cysteine residue. These compounds weaken ubiquitin binding, thereby inhibiting the deubiquitinating enzyme activity of USP7. The interaction of GNE-6640 and GNE-6776 with acidic residues mediating hydrogen-bonded interactions with the Lys48 side chain suggests that USP7 preferentially interacts with and cleaves ubiquitin molecules with free Lys48 side chains. We validated this hypothesis by constructing biubiquitin chains with different proximal and distal isotopic labels and measuring USP7 binding using NMR. This preferential binding prolonged the depolymerization kinetics of the Lys48-linked ubiquitin chain relative to the Lys63-linked ubiquitin chain. In conclusion, the design of compounds that inhibit USP7 activity by weakening ubiquitin binding provides an opportunity for the development of other deubiquitinating enzyme inhibitors and may be a more broadly applicable strategy for inhibiting proteins that require ubiquitin binding to exert their full functional activity. [1] This article describes GNE-6640 and GNE-6776, selective USP7 inhibitors with well-defined inhibitory mechanisms. A rigorous screening process is essential for selecting and optimizing targeted inhibitors. A joint study revealed previously undescribed interactions between USP7 deubiquitinating enzyme activity and PIM kinase in regulating cell viability. The co-crystal structures of GNE-6640 or GNE-6776 indicate that complementary charged interactions between USP7-D305/E308 and the ubiquitin-K48 side chain are crucial, a finding confirmed by mutation analysis. Notably, D305G has been identified as a somatic loss-of-function mutant from patients with acute lymphoblastic leukemia²¹. NMR analysis of USP7 binding to native monoubiquitin and differentially labeled diubiquitin showed that USP7 preferentially interacts with the ubiquitin moiety with a free K48 side chain. Some studies have suggested that certain deubiquitinating enzymes cannot effectively unpolymerize long substrate-bound K48 linkages, thus setting a threshold for proteasome-targeted polyubiquitination²²; our study confirms this view and provides a biophysical mechanism. Many proteins, including other deubiquitinating enzymes, ubiquitin ligases, DNA repair and endocytosis mechanisms, and epigenetic regulators, depend on ubiquitin binding for their function²³. Developing selective inhibitors that can weaken ubiquitin binding is an effective strategy for inhibiting USP7. Our study demonstrates the feasibility of this approach and may have broader applications in inhibiting other types of ubiquitin-binding proteins. [1]

C21H21N3O2

347.41

348.16

C, 68.95; H, 5.79; N, 16.08; O, 9.18

2009273-60-1

122531799

Off-white to light yellow solid powder

3.5

3

4

4

26

456

0

UCYSSYGGXOFJKK-UHFFFAOYSA-N

InChI=1S/C20H20N4O2/c1-3-15-16(13-6-9-17(23-10-13)20(26)22-2)11-24-19(21)18(15)12-4-7-14(25)8-5-12/h4-11,25H,3H2,1-2H3,(H2,21,24)(H,22,26)

6'-Amino-4'-ethyl-5'-(4-hydroxyphenyl)-N-methyl-[3,3'-bipyridine]-6-carboxamide

2934.99.03.00

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Solubility in Formulation 1: ≥ 2.08 mg/mL (5.99 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

Solubility in Formulation 2: ≥ 2.08 mg/mL (5.99 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

---

View More

Solubility in Formulation 3: ≥ 2.08 mg/mL (5.99 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

---

 (Please use freshly prepared in vivo formulations for optimal results.)